Implementing Alternative Payment Models for Improved Population Health: Experiences From the OCM

Bringing the bispecific T-cell engager into the frontline consolidation phase "redefines the standard of care" for patients with B-ALL, an investigator said.

Kheir Mugwaneza, the lead project manager of the Immigrant and Refugee Health Program at Allegheny Health Network, discusses how the program is working to address gaps in care for this community.

The results of the 3-year follow-up show meaningful improvement in overall survival (OS) and progression-free survival (PFS) for tislelizumab plus chemotherapy compared with placebo plus chemotherapy.

Continuing with our Pride Month podcast series, in this episode we speak with Perry Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, and James F. Dougherty, VMD, MS, current member of Rutgers' Board of Governors.

Adults aged 70 and older were significantly more likely to develop congestive heart failure if they also experienced olfactory impairment.

Neurotrophic tyrosine receptor kinase (NTRK)–positive locally advanced or metastatic solid tumors can now be treated with the first FDA-approved treatment option.